Clearmind Submits FDA Recommendations for Non-Hallucinogenic Psychedelic Therapies
Event summary
- Clearmind submitted recommendations to the FDA under Docket No. FDA-2026-N-7542, focusing on non-hallucinogenic neuroplastogens for Alcohol Use Disorder (AUD).
- The company highlighted clinical trials at Yale and Johns Hopkins, emphasizing potential for self-administration and at-home therapies.
- Clearmind called for streamlined regulatory pathways, expanded clinical trial access, and Breakthrough Designation for psychedelic-derived therapies.
- The submission follows recent engagements with U.S. federal agencies, including responses to HHS and an FDA-convened panel briefing in September 2026.
The big picture
Clearmind’s submission to the FDA reflects the growing push for regulatory clarity in the psychedelic therapy space, particularly for non-hallucinogenic compounds. The company’s engagement with federal agencies underscores the strategic importance of securing government support for clinical trials and patient access. As the industry seeks to balance innovation with safety, Clearmind’s recommendations could set a precedent for future regulatory frameworks in mental health treatment.
What we're watching
- Regulatory Pathways
- Whether the FDA will adopt Clearmind’s recommendations for streamlined approval processes for non-hallucinogenic psychedelic therapies.
- Clinical Validation
- The pace at which data from Yale and Johns Hopkins trials will influence broader acceptance of neuroplastogens for AUD.
- Government Collaboration
- How potential partnerships with VA, DoW, and HHS could accelerate the development and deployment of psychedelic-derived treatments.
